India's Aarti Drugs falls as US FDA issues inspectional observations

Aarti Drugs

26/09/2024 07:32

** Shares of Aarti Drugs  ADRG.NS  fall as much as 2% to
510.20 rupees
    ** Drugmaker says its API manufacturing facility at Tarapur
in Maharashtra, has received seven inspectional observations in
Form 483 from the U.S. FDA
    **  A Form 483 is a type of agency report containing
observations that FDA inspectors deem to be objectionable
    ** Stock on track for a third consecutive session of loss
    ** Stock last down 1%, cutting YTD gains to 5.4%

 (Reporting by Ashish Chandra in Bengaluru)
 ((ashish.chandra@thomsonreuters.com (+91 7982114624))